(Q36458423)

14 August 2017

1 reference

title

Emerging drugs for eating disorder treatment (English)

1 reference

14 August 2017

1 reference

James Edward Mitchell

series ordinal

3

object named as

James E Mitchell

1 reference

14 August 2017

Kristine J Steffen

1

1 reference

14 August 2017

James L Roerig

series ordinal

2

1 reference

14 August 2017

Saritha Uppala

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

2

1 reference

14 August 2017

315-336

1 reference

Personality dimensions in eating disorders and their relevance for subtyping

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

The validity of the distinction between bulimia with and without anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Investigational drugs for eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Comorbidity of anxiety disorders with anorexia and bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Clinical practice. Anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Psychiatric comorbidity in anorexia and bulimia nervosa: nature, prevalence, and causal relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Impulsivity and compulsivity in bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

The prevalence of DSM-IV personality pathology among individuals with bulimia nervosa, binge eating disorder and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Recent research of relationships among eating disorders and personality disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Medical and psychiatric morbidity in obese women with and without binge eating

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Self-harm and substance use in a community sample of Black and White women with binge eating disorder or bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Long-term outcome of antidepressant treatment for bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Available pharmacological treatments for anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

New targets in the treatment of anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Zinc deficiency in anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

A placebo-controlled crossover study of oral clonidine in acute anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Oesophageal and gastric motility disorders in patients categorised as having primary anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Gastric emptying, body weight and symptoms in primary anorexia nervosa. Long-term effects of cisapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

A randomized secondary treatment study of women with bulimia nervosa who fail to respond to CBT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

High levels of free testosterone in women with bulimia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Polycystic ovarian morphology and bulimia nervosa: a 9-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Reboxetine in the treatment of bulimia nervosa: a report of seven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Use of reboxetine in bulimia nervosa: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Phenytoin treatment of the binge-eating syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Milnacipran in the treatment of bulimia nervosa: a report of 16 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Drug therapy for patients with eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Sibutramine: a novel new agent for obesity treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Effect of orlistat in obese patients with binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Hypocretins (orexins) and sleep-wake disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Inhibitory effect of exogenous orexin a on gastric emptying, plasma leptin, and the distribution of orexin and orexin receptors in the gut and pancreas in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

The gut hormone peptide YY regulates appetite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Gut hormone PYY(3-36) physiologically inhibits food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Ghrelin enhances appetite and increases food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: relations with eating patterns and circulating concentrations of cortisol and thyroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Neurosteroid metabolism in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Functional role, structure, and evolution of the melanocortin-4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Current and investigational antiobesity agents and obesity therapeutic treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Brain regulation of food intake and appetite: molecules and networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Case study: anorexia nervosa and autistic disorder in an adolescent girl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Case reports of olanzapine treatment of anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Olanzapine in the treatment of anorexia nervosa: an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.315

10.1517/14728214.11.2.315

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference